User profiles for Jennifer Faber

Jennifer Faber

Center of Neurology, Dept. of Neuroradiology, and DZNE
Verified email at dzne.de
Cited by 1262

Natural history, phenotypic spectrum, and discriminative features of multisystemic RFC1 disease

A Traschütz, A Cortese, S Reich, N Dominik, J Faber… - Neurology, 2021 - AAN Enterprises
Objective To delineate the full phenotypic spectrum, discriminative features, piloting longitudinal
progression data, and sample size calculations of replication factor complex subunit 1 (…

Neurofilaments in spinocerebellar ataxia type 3: blood biomarkers at the preataxic and ataxic stage in humans and mice

C Wilke, E Haas, K Reetz, J Faber… - EMBO molecular …, 2020 - embopress.org
With molecular treatments coming into reach for spinocerebellar ataxia type 3 ( SCA 3),
easily accessible, cross‐species validated biomarkers for human and preclinical trials are …

In vivo patterns of tau pathology, amyloid-β burden, and neuronal dysfunction in clinical variants of Alzheimer's disease

…, GN Bischof, B Von Reutern, J Faber… - Journal of …, 2017 - content.iospress.com
The clinical heterogeneity of Alzheimer’s disease is not reflected in the rather diffuse cortical
deposition of amyloidß. We assessed the relationship between clinical symptoms, in vivo …

Relationships between personality characteristics of people who stutter and the impact of stuttering on everyday life

B Bleek, M Reuter, JS Yaruss, S Cook, J Faber… - Journal of fluency …, 2012 - Elsevier
OBJECTIVE: This study investigates the association between the five-factor model of personality
measured by the NEO Five-Factor Inventory (NEO-FFI) and the Overall Assessment of …

Regional brain and spinal cord volume loss in spinocerebellar ataxia type 3

J Faber, T Schaprian, K Berkan, K Reetz… - Movement …, 2021 - Wiley Online Library
Background Given that new therapeutic options for spinocerebellar ataxias are on the
horizon, there is a need for markers that reflect disease‐related alterations, in particular, in the …

Tau and neurofilament light‐chain as fluid biomarkers in spinocerebellar ataxia type 3

…, C Januário, J Infante, J Faber… - European journal of …, 2022 - Wiley Online Library
Background and purpose Clinical trials in spinocerebellar ataxia type 3 (SCA3) will require
biomarkers for use as outcome measures. Methods To evaluate total tau (t‐tau), glial fibrillary …

Clinically meaningful magnetic resonance endpoints sensitive to preataxic spinocerebellar ataxia types 1 and 3

…, G Banan, R Valabregue, P Ehses, J Faber… - Annals of …, 2023 - Wiley Online Library
Objective This study was undertaken to identify magnetic resonance (MR) metrics that are
most sensitive to early changes in the brain in spinocerebellar ataxia type 1 (SCA1) and type 3 …

Development of SARAhome, a New Video‐Based Tool for the Assessment of Ataxia at Home

M Grobe‐Einsler, A Taheri Amin, J Faber… - Movement …, 2021 - Wiley Online Library
Background Clinical scales such as the Scale for the Assessment and Rating of Ataxia (SARA)
cannot be used to study ataxia at home or to assess daily fluctuations. The objective of …

Tau pathology and cognitive reserve in Alzheimer's disease

MC Hoenig, GN Bischof, J Hammes, J Faber… - Neurobiology of …, 2017 - Elsevier
Cognitive reserve (CR) is defined as the ability to maintain functionality despite accumulating
pathology. Education has been used as a proxy for CR. For example, by using positron …

[HTML][HTML] CerebNet: A fast and reliable deep-learning pipeline for detailed cerebellum sub-segmentation

J Faber, D Kügler, E Bahrami, LS Heinz, D Timmann… - Neuroimage, 2022 - Elsevier
Quantifying the volume of the cerebellum and its lobes is of profound interest in various
neurodegenerative and acquired diseases. Especially for the most common spinocerebellar …